EU Approves AstraZeneca's Etcamah for ER+ Breast Cancer with ESR1 Mutation

summarizeSummary

AstraZeneca secured EU approval for Etcamah, a new oral drug for advanced ER-positive breast cancer with ESR1 mutations, offering a significant new treatment option with strong efficacy.

check_boxKey Events · Product Development and Regulatory · AZN

• EU Approval for Etcamah

  Etcamah (camizestrant) in combination with a CDK4/6 inhibitor received EU approval for the treatment of adult patients with ER-positive, HER2-negative locally advanced or metastatic breast cancer upon detection of an ESR1 mutation and without disease progression during 1st-line endocrine therapy.

• Strong Efficacy Data

  The approval was based on positive results from the pivotal SERENA-6 Phase III trial, which showed the Etcamah combination reduced the risk of disease progression or death by 56%.

• First-in-Class Designation

  Etcamah is highlighted as the first and only next-generation oral SERD and complete ER antagonist approved in 1st-line for this indication, and the only option combinable with all widely approved CDK4/6 inhibitors.

• Pipeline Progress

  This approval marks Etcamah as the 11th new AstraZeneca medicine out of 20 expected to launch by 2030, demonstrating continued pipeline execution.

auto_awesomeAnalysis · AZN · Life Sciences

This approval introduces Etcamah as the first and only next-generation oral SERD for 1st-line advanced ER-positive, HER2-negative breast cancer with an ESR1 mutation in the EU. The drug demonstrated a 56% reduction in disease progression or death in trials, offering a new standard of care for patients who develop resistance to existing therapies. This expands AstraZeneca's oncology portfolio and strengthens its position in the breast cancer market.